Inhibrx Biosciences

INBXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.649 B

$112.04 +2.46%

Close of 21 Sept 2026

Revenue

$1.30M

#3462 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

14,717,660

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#38NovavaxNVAX$1.72B
#39ImmunocoreIMCR$1.66B
#40Inhibrx BiosciencesINBX$1.65B
#41Taysha Gene TherapiesTSHA$1.64B
#42Cullinan TherapeuticsCGEM$1.37B

What if Inhibrx Biosciences were worth as much as…

Open the what-if tool →

Gold $30.3T

$2,056,988

Per share 18,359× higher

Bitcoin $1.72T

$116,853.07

Per share 1,043× higher

Nvidia $5.48T

$372,332.15

Per share 3,323× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Inhibrx Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.